ClinicalTrials.gg
TerminatedNCT03810469DELTA-PERFUpdated Oct 22, 2026

Foot Perfusion Analysis to Predict Limb Salvage

An observational study in Critical Limb Ischemia and Peripheral Arterial Disease, sponsored by Centre Hospitalier de Valenciennes. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Hospitalier de Valenciennes · Observational

How we know

Why this study was terminated
COVID-19 disrupted recruitment and follow-up in 2020. Following the investigators' departure, recruitment could not resume, leading to premature study termination.
Updated Oct 22, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
69
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Chronic Limb-Threatening Ischemia with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · France.

Enrollment
8th of 11
69 · median 300
Started
2019
with 1 other
Observational
11 of 22
4 open now
Registered
9th of 22
by date
Lead sponsor
1 of 22
Centre Hospitalier de Valenciennes

Among the 22 studies in Chronic Limb-Threatening Ischemia with a site in France, this one is the 8th largest by enrollment of the 11 observational ones that give a count, is one of 2 that started in 2019, is one of 11 observational ones, and was the 9th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 22 studies in Chronic Limb-Threatening Ischemia with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Limb-Threatening Ischemia with a site in France, or all of them as a file.
02

Study summary

This study aims at evaluating the correlation between foot perfusion on angiographies performed before and after revascularization and limb salvage in patients with critical limb ischemia.

Read the detailed description

Critical limb ischemia (CLI) in diabetic patients is increasing drastically worldwide, and is already recognized as a major health issue. CLI is frequently leading to major amputations. Therefore, one of the key point to prevent limb loss is to restore a good vascularization to the foot, usually thanks to endovascular means.

No consensual indicator is currently available to estimate if the limb revascularization will be sufficient or not to prevent amputation, and to help physicians decide if they should be more aggressive during the endovascular procedure. Transcutaneous oximetry and value of the ankle-brachial index (ABI) are commonly used in the ward (not available in the operating room), but have shown poor correlation to wound healing or limb salvage and results are frequently biased because of the arterial wall calcifications due to diabetes. Value of the first toe systolic pressure is currently under evaluation to predict survival without amputation, with promising results, but cannot be applied to patients with wounds at this level or previous minor amputation.

The emergence of hybrid rooms in the operating theater offer access to high quality imaging and image post-treatment. Those capabilities could be used to analyze the flow and the tissue perfusion in the foot, and correlate those imaging parameters to positive clinical outcomes, such as wound healing, thus creating a useful tool to guide physicians in daily practice.

Differences between foot angiographies performed before and after revascularization could be used to estimate the quality of the revascularization and predict wound healing and limb salvage. This method would be directly available in the operating room and could help physicians to optimize their strategy during the procedure

03

Conditions studied

  • Critical Limb Ischemia
  • Peripheral Arterial Disease

Keywords

  • limb salvage
  • foot perfusion
  • hybrid room
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients suffering from peripheral arterial disease in critical limb ischemia (Rutherford 4, 5 and 6) at the initial presentation, with a major risk of limb amputation at mid-term without revascularization.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with critical limb ischemia Rutherford 4, 5 and 6, with at least one pre-operative exam (CTA, magnetic resonance angiography or ultrasound) demonstrating a peripheral arterial disease, and requiring an endovascular or hybrid (meaning combined with a surgical technique) revascularization of the lower limb.

Exclusion criteria

Exclusion Criteria:

  • Patients not willing to give their consent to study enrollment
  • Patients under 18 years old
  • Patients with severe renal insufficiency (estimated \< 30 mL/min), without dialysis
  • Patients with life threatening septic wounds who would require an amputation at the initial presentation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
69 participants (actual)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of participants with major amputation

    Major amputations are defined as below or above the knee amputations on the treated limb. This is a clinical binary criterion (0=Freedom from major amputation, 1=Major amputation)

    Time frame: 1 month

  2. Number of participants with major amputation

    Major amputations are defined as below or above the knee amputations on the treated limb. This is a clinical binary criterion (0=Freedom from major amputation, 1=Major amputation)

    Time frame: 3 months

  3. Number of participants with major amputation

    Major amputations are defined as below or above the knee amputations on the treated limb. This is a clinical binary criterion (0=Freedom from major amputation, 1=Major amputation)

    Time frame: 6 months

  4. Number of participants with major amputation

    Major amputations are defined as below or above the knee amputations on the treated limb. This is a clinical binary criterion (0=Freedom from major amputation, 1=Major amputation)

    Time frame: 1 year

Secondary outcomes

  1. Wound Healing

    Complete wound Healing at the level of the foot according to the WiFI classification

    Time frame: 1 month

  2. Wound Healing

    Complete wound Healing at the level of the foot according to the WiFI classification

    Time frame: 3 months

  3. Wound Healing

    Complete wound Healing at the level of the foot according to the WiFI classification

    Time frame: 6 months

  4. Wound Healing

    Complete wound Healing at the level of the foot according to the WiFI classification

    Time frame: 1 year

  5. Number of patients with secondary intervention

    Number of participants with a secondary intervention. Secondary intervention is defined as all secondary surgical interventions (both endovascular and open repairs) associated to critical limb ischemia on the same limb. It includes secondary angioplasties, bypasses or minor and major amputations. This is a clinical binary criterion (0= Freedom from secondary intervention, 1=At least one secondary intervention)

    Time frame: 1 year

  6. Overall Mortality

    Overall Mortality, all-cause included

    Time frame: 1 year

07

Study locations

1 site
  • CH Valenciennes
    Valenciennes, 59322, France
08

References and documents

Publications

  • Brownrigg JR, Apelqvist J, Bakker K, Schaper NC, Hinchliffe RJ. Evidence-based management of PAD & the diabetic foot. Eur J Vasc Endovasc Surg. 2013 Jun;45(6):673-81. doi: 10.1016/j.ejvs.2013.02.014. Epub 2013 Mar 27. PubMed 23540807 ↗
  • Wang Z, Hasan R, Firwana B, Elraiyah T, Tsapas A, Prokop L, Mills JL Sr, Murad MH. A systematic review and meta-analysis of tests to predict wound healing in diabetic foot. J Vasc Surg. 2016 Feb;63(2 Suppl):29S-36S.e1-2. doi: 10.1016/j.jvs.2015.10.004. PubMed 26804365 ↗
  • Wickstrom JE, Laivuori M, Aro E, Sund RT, Hautero O, Venermo M, Jalkanen J, Hakovirta H. Toe Pressure and Toe Brachial Index are Predictive of Cardiovascular Mortality, Overall Mortality, and Amputation Free Survival in Patients with Peripheral Artery Disease. Eur J Vasc Endovasc Surg. 2017 May;53(5):696-703. doi: 10.1016/j.ejvs.2017.02.012. Epub 2017 Mar 11. PubMed 28292565 ↗
  • Brownrigg JR, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE, Schaper NC; International Working Group on the Diabetic Foot. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:128-35. doi: 10.1002/dmrr.2704. PubMed 26342129 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2019 to primary completion in Apr 2022, 38 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Oct 2021 → Apr 2022 and completion Feb 2022 → Apr 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2019
First posted
Jan 18, 2019
StartActual
Feb 1, 2019
Primary completionActual
Apr 4, 2022was Oct 2021
CompletionActual
Apr 4, 2022was Feb 2022
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated COVID-19 disrupted recruitment and follow-up in 2020. Following the investigators' departure, recruitment could not resume, leading to premature study termination.
changed Oct 22, 2026
Primary completion
Oct 2, 2021→Apr 4, 2022 (actual)
Oct 22, 2026
Study completion
Feb 1, 2022→Apr 4, 2022 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Terminated
    Why stopped COVID-19 disrupted recruitment and follow-up in 2020. Following the investigators' departure, recruitment could not resume, leading to premature study termination.
    Primary completion Oct 2, 2021→Apr 4, 2022 (now actual)
    Study completion Feb 1, 2022→Apr 4, 2022 (now actual)
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03810469
Lead sponsor
Centre Hospitalier de Valenciennes
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Feb 1, 2019
Primary completion
Apr 4, 2022
Completion
Apr 4, 2022
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion